Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Current Quarter	$NA	Next Quarter	$NA
Current Year	$-0.16	Next Year	$NA
QoQ Growth	NaN%	YoY Growth	NaN%
3Y EPS CAGR	+22.9%	Target Price	$5.25
Consensus	Buy	Upside	+25.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABUS	$4.20	+0.72%	867.78K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABUS	$4.20	+0.7%	867.78K
3
4
5
6

ABUS

ABUS

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Arbutus Biopharma Corporation Data in Excel

Get Arbutus Biopharma Corporation Data in Excel